Cookie Notice
By continuing to use this website, you consent to our use of cookies and the other terms of our Privacy Policy.
For more information, please visit our Privacy Policy.
A mucoactive agent* that fits into patients' lives
*The precise mechanism of action of BRONCHITOL in improving pulmonary function in cystic fibrosis (CF) patients is unknown.
BRONCHITOL is not intended to be used as a rescue medication. Inhaler and blister pack are not actual size and are for representation only. Use an inhaled bronchodilator 5–15 minutes before taking BRONCHITOL.
Starting a patient on BRONCHITOL® (mannitol) inhalation powder
Marty Solomon, MD, reviews key information that HCPs should know when starting a patient on BRONCHITOL.
BRONCHITOL® (mannitol) inhalation powder—the first and only dry powder inhaled mucoactive agent* for patients with CF
The BRONCHITOL inhaler is:
- Compact, handheld
- Discreet
- Portable
BRONCHITOL requires no:
- Nebulization
- Refrigeration
- Routine cleaning or maintenance
The precise mechanism of action of BRONCHITOL in improving pulmonary function in cystic fibrosis (CF) patients is unknown.
BRONCHITOL
dosing and administration
How to administer
BRONCHITOL is not intended to be used as a rescue medication. Inhaler and blister pack are not actual size and are for representation only. Use an inhaled bronchodilator 5–15 minutes before taking BRONCHITOL.
In clinical studies, administration time for BRONCHITOL was approximately 5 minutes. However, administration times may vary depending on patient-specific factors.
BRONCHITOL improves FEV1
Patients taking BRONCHITOL experienced sustained improvements in FEV1 vs control over 26 weeks.1
Review the clinical data
Important Safety Information
BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).
Please see Full Prescribing Information.
Consider these potential BRONCHITOL patients
Review profiles of potential patients for whom BRONCHITOL may be appropriate.
See the profiles
Chiesi CareDirect® is here to help
Discover the support benefits and services available to your eligible patients.
Learn about Chiesi CareDirect
Important Safety Information
BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).
BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.
Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.
Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.
Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.
Indication
BRONCHITOL® (mannitol) inhalation powder is a sugar alcohol indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years of age and older with cystic fibrosis. Use BRONCHITOL only in adults who have passed the BRONCHITOL Tolerance Test.
Reference: 1. BRONCHITOL® (mannitol) inhalation powder Prescribing Information. 2020.